Advancing Neurodegenerative Drug Discovery with a New Class of Consistent, Scalable Human iPSCDerived cells

Time: 12:30 pm - 1:40 pm
day: Track A - Day 1 AM


  • Discovering how next generation precision reprogramming technology, opti-ox(TM), is overcoming the inefficiencies
    and inconsistencies of current cell generation methods
  •  Understanding how precision reprogramming is powering a new class of rapidly maturing, consistent and scalable
    human iPSC-derived cells (glutamatergic neurons, GABAergic neurons and microglia) and associated disease models for neurodegenerative disorders such as Gaucher’s, Huntington’s and Parkinson’s disease
  • Exploring insights into CNS drug discovery case studies, Compatibility of ioGlutamatergic Neurons for high throughout screening and the application of optiox powered GBA and Parkinson’s disease models in functional phenotypic screens